Effects of Antidiabetic Drugs on Glucose Tolerance in Streptozotocin-nicotinamide-induced Mildly Diabetic and Streptozotocin-induced Severely Diabetic Mice

Abstract

In this study, streptozotocin-nicotinamide-induced mildly diabetic mice and streptozotocin-induced severely diabetic mice were created to compare their characteristics and to investigate the effects of antidiabetic drugs on glucose tolerance. In severely diabetic mice, the pancreatic insulin content decreased to approximately 10% of levels found in normal mice. These mice also showed a decrease in body weight, a marked increase in nonfasting blood glucose levels and urinary glucose excretion, and a marked decline in glucose tolerance due to insulin secretory deficiency. In contrast, the pancreatic insulin content was approximately 50% of normal levels in mildly diabetic mice. These mice did not show any change in body weight, but displayed a mild increase in nonfasting blood glucose levels and urinary glucose excretion, and a mild decline in glucose tolerance due to loss of early-phase insulin secretion. Administration of antidiabetic drugs, namely voglibose, metformin, glibenclamide, sitagliptin and insulin, significantly improved glucose tolerance in mildly diabetic mice. In severely diabetic mice, voglibose, metformin and insulin significantly improved glucose tolerance, but no significant effect was observed for glibenclamide and sitagliptin due to a decreased insulinotropic effect. These results demonstrate that streptozotocin-nicotinamide-induced mildly diabetic mice have many pathological features resembling type 2 diabetes, and can serve as models for the pharmacological evaluation of many antidiabetic drugs.

Key words

diabetes - glucose tolerance - voglibose - metformin - glibenclamide - sitagliptin - insulin

References

• 1 Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: an overview.  Indian J Med Res. 2007;  125 451-472
• 2 Ladriere L, Malaisse-Lagae F, Fuhlendorff J, Malaisse WJ. Repaglinide, glibenclamide and glimepiride administration to normal and hereditarily diabetic rats.  Eur J Pharmacol. 1997;  335 227-234
• 3 Efanov AM, Appelskog IB, Abdel-Halim SM, Khan A, Branstrom R, Larsson O, Ostenson CG, Mest HJ, Berggren PO, Efendic S, Zaitsev SV. Insulinotropic activity of the imidazoline derivative RX871024 in the diabetic GK rats.  Am J Physiol. 2002;  282 E117-E124
• 4 Portha B, Serradas P. Improvement in glucose-induced insulin secretion in diabetic rats after long-term gliclazide treatment: a comparative study using different models of non-insulin-dependent diabetes mellitus induced by neonatal streptozotocin.  Am J Med. 1991;  90 15S-21S
• 5 Ikenoue T, Okazaki K, Fujitani S, Tsuchiya Y, Akiyoshi M, Maki T, Kondo N. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropylcyclohexane- carbonyl)-D-phynylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide.  Biol Pharma Bull. 1997;  20 354-359
• 6 Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats.  Diabetologia. 1999;  42 1324-1331
• 7 Sudre B, Broqua P, White RB, Ashworth D, Evans DM, Haigh R, Junien JL, Aubert ML. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats.  Diabetes. 2002;  51 1461-1469
• 8 Mine T, Miura K, Kitahara Y, Okano A, Kawamori R. Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide.  Biol Pharma Bull. 2002;  25 1412-1416
• 9 Farrar NS, Chambers NJ, Carlsson AR, Denyer G, Johnston GA. Effect of a series of novel sulphonylthioureas on glucose tolerance in the obese fa/fa Zucker rat.  Clin Exp Pharmacol Physiol. 2001;  28 386-391
• 10 Pieper AA, Brat DJ, Krug DK, Watkins CC, Gupta A, Blackshaw S, Verma A, Wang ZQ, Snyder SH. Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes.  Proc Natl Acad Sci USA. 1999;  96 3059-3064
• 11 Burkart V, Wang ZQ, Radons J, Heller B, Herceg Z, Stingl L, Wagner EF, Kolb H. Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozotocin.  Nature Med. 1999;  5 314-319
• 12 Shima K, Hirota M, Sato M, Numoto S, Oshima I. Effect of poly(ADP-ribose) synthetase inhibitor administration to streptozotocin-induced diabetic rats on insulin and glucagon contents in their pancreas.  Diabetes Res Clin Pract. 1987;  3 135-142
• 13 Oguri S, Motegi K, Endo Y. Augmented lipopolysaccharide-induction of the histamine-forming enzyme in streptozotocin-induced diabetic mice.  Biochim Biophys Acta. 2003;  1637 83-90
• 14 LeDoux SP, Hall CR, Forbes PM, Patton NJ, Wilson GL. Mechanisms of nicotinamide and thymidine protection from alloxan and streptozotocin toxicity.  Diabetes. 1988;  37 1015-1019
• 15 Masiello P, Broca C, Gross R, Roye M, Manteghetti M, Hillaire-Buys D, Novelli M, Ribes G. Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide.  Diabetes. 1998;  47 224-229
• 16 Ichikawa K, Yamato T, Ojima K, Tsuji A, Ishikawa K, Kusama H, Kojima M. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats.  Clin Exp Pharmacol Physiol. 2002;  29 423-427
• 17 Berthiaume N, Zinker BA. Metabolic responses in a model of insulin resistance: Comparison between oral glucose and meal tolerance tests.  Metabolism. 2002;  51 595-598
• 18 Like AA, Rossini AA. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus.  Science. 1976;  193 415-417
• 19 Casirola DM, Ferraris RP. α-Glucosidase inhibitors prevent diet-induced increases in intestinal sugar transport in diabetic mice.  Metabolism. 2006;  55 832-841
• 20 Matsuo T, Odaka H, Ikeda H. Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes.  Am J Clin Nutr. 1992;  55 314S-317S
• 21 Odaka H, Shino A, Ikeda H, Matsuo T. Antiobesity and antidiabetic actions of a new potent disaccharidase inhibitor in genetically obese-diabetic mice, KKA^y.  J Nutr Sci Vitaminol. 1992;  38 27-37
• 22 Azuma K, Toyofuku Y, Iesaki T, Otsuka A, Tanaka A, Mita T, Hirose T, Tanaka Y, Daida H, Kawamori R, Watada H. Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation.  Biochem Biophys Res Commun. 2006;  345 688-693
• 23 Cheng JT, Huang CC, Liu IM, Tzeng TF, Chang CJ. Novel mechanism for plasma glucose-lowering action of metformin in streptozotocin-induced diabetic rats.  Diabetes. 2006;  55 819-825
• 24 El-Atat F, MacFarlane SI, Sowers JR. Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management.  Curr Hypertens Rep. 2004;  6 215-223
• 25 Santeusanio F, Loreto C Di, Lucidi P, Murdolo G, De Cicco A, Parlanti N, Piccioni F, De Feo P. Diabetes and exercise.  J Endocrinol Invest. 2003;  26 937-940

Correspondence